Are sodium‐glucose cotransporter‐2 inhibitors safe adjunctive drugs during insulin therapy in young children with type 1 diabetes? The first case of type 1 diabetes with SLC5A2 mutation

Documenti analoghi

• Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
  di: Jincheng Shen, et al.
  Pubblicazione: (2025)
• Clinical use and monitoring of adverse effects of sodium‐glucose cotransporter‐2 inhibitors in persons with type 1 diabetes mellitus
  di: Chinatsu Sakai, et al.
  Pubblicazione: (2025)
• Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
  di: Keiko Maruyama‐Sakurai, et al.
  Pubblicazione: (2024)
• Effect of sodium–glucose cotransporter 2 inhibitors on serum low‐density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus
  di: Tasuku Imada, et al.
  Pubblicazione: (2024)
• Risk of insulin initiation with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: A real‐world claims database study in Japan
  di: Ryo Suzuki, et al.
  Pubblicazione: (2025)